Health

No Image

It's Not Just What You Make, It's Where You Live, Study On Life Expectancy Says

A woman jogs in Oakland, Calif., last February. Healthier lifestyles may be a reason why poor people live longer in some cities than others.

A woman jogs in Oakland, Calif., last February. Healthier lifestyles may be a reason why poor people live longer in some cities than others. Ben Margot/AP hide caption

toggle caption Ben Margot/AP

Poor people who reside in expensive, well-educated cities such as San Francisco tend to live longer than low-income people in less affluent places, according to a study of more than a billion Social Security and tax records.

The study, published in The Journal of the American Medical Association, bolsters what was already well known — the poor tend to have shorter lifespans than those with more money. But it also says that among low-income people, big disparities exist in life expectancy from place to place, said Raj Chetty, professor of economics at Stanford University.

“There are some places where the poor are doing quite well, gaining just as much in terms of life span as the rich, but there are other places where they’re actually going in the other direction, where the poor are living shorter lives today than in they did in the past,” Chetty said, in an interview with NPR.

For example, low-income people in Birmingham, Ala., live about as long as the rich, but in Tampa, Fla., the poor have actually lost ground.

Chetty and his co-authors collected more than 1.4 billion records from the Social Security Administration and the Internal Revenue Service to try to measure the relationship between income and life expectancy.

“There are vast gaps in life expectancy between the richest and poorest Americans,” Chetty said. “Men in the top 1 percent distribution level live about 15 years longer than men in the bottom 1 percent on the income distribution in the United States.

“To give you a sense of the magnitude, men in the bottom one percent have life expectancy comparable to the average life expectancy in Pakistan or Sudan.”

And where lifespans are concerned the rich are getting richer.

Since 2001, life-expectancy has increased by 2.3 years for the wealthiest 5 percent of American men and by nearly 3 percent for similarly situated women. Meanwhile, life expectancy has increased barely at all for the poorest 5 percent.

Among the study’s findings was that poor people in affluent cities such as San Francisco and New York tend to live longer than people of similar income levels in rust belt cities such as Detroit, he said.

What accounts for the disparity isn’t clear, Chetty says.

It may be that some cities such as San Francisco may be better at promoting healthier lifestyles, with smoking bans, for example, or perhaps people tend to adopt healthier habits if they live in a place where everyone else is doing it, he says.

The study suggests that the relationship between life expectancy and income is not iron-clad, and changes at the local level can make a big difference.

“What our study shows is that thinking about these issues of inequality and health and life expectancy at a local level is very fruitful, and thinking about policies that change health behaviors at a local level is likely to be important,” he says.

Chetty notes that the study has clear implications for Social Security and Medicare. The fact that poor people don’t live as long means they are paying into the system without getting the same benefits, a fact that needs to be considered in any discussion about raising the retirement age, he says.

The study was co-authored by Michael Stepner and Sarah Abraham of the Massachusetts Institute of Technology; Benjamin Scuderi, David Culter and Augustin Bergeron of Harvard University; Shelby Lin of McKinsey and Co.; and Nicholas Turner of the U.S. Treasury Department’s Office of Tax Analysis.

Let’s block ads! (Why?)


No Image

When The Cost Of Care Triggers A Medical Deportation

Lorenzo Gritti for NPR

Lorenzo Gritti for NPR

In an emergency, hospitals, by law, must treat any patient in the U.S. until he or she is stabilized, regardless of the patient’s immigration status or ability to pay.

Yet, when it comes time for the hospitals to discharge these patients, the same standard doesn’t apply.

Though hospitals are legally obligated to find suitable places to discharge patients (for example, to their homes, rehabilitation facilities or nursing homes), their insurance status makes all the difference.

Several years ago I began caring for a man who’d been in our hospital for more than three months. He was in his 50s and had suffered a stroke. Half his body was paralyzed and he couldn’t swallow food. After weeks of intensive physical, occupational and speech therapy, he regained his abilities to eat, drink and walk with only minimal help. But he still wasn’t well enough to live on his own, prepare food or even get to the toilet by himself.

Ideally, we would have discharged him from the hospital to a rehabilitation facility so he could continue therapy and make more progress toward his prestroke state.

But our plan faced insurmountable barriers. First off, the patient was an immigrant who had entered the country illegally. Second, he didn’t have insurance.

Because he lacked health coverage, no other facility would accept him. His immigration status meant that we couldn’t find an outside charity that would cover the costs of his care or pay for insurance.

Our comparatively expensive acute care hospital was therefore compelled to hold him — with the meter running. After another month, it began to seem that he’d become a permanent resident of our hospital ward.

“Could he go back to Mexico?” our case manager asked.

We were startled. No one on my team had ever experienced a situation like this, so we began researching the possibility. As it turned out, it’s a murky legal and ethical area that drew some public attention after an expose in The New York Times in 2008.

Nevertheless, our hospital faced a real financial burden, and the case manager pressed on. After reaching the patient’s family in Mexico, and discussing issues with the Mexican consulate, the case manager began making travel arrangements to a rehabilitation hospital in Mexico.

Medical air transport to another country is an expensive proposition — roughly $50,000, depending on the equipment needed and the distance to the receiving facility in the patient’s home nation.

From the hospital’s point of view, it was easy to see that this large one-time expense would be worthwhile. The transfer to Mexico would put a stop to the indefinite, uncompensated costs of continued hospitalization. Further, the transfer would open up the patient’s bed to a new (and presumably insured) patient.

After several meetings between our medical team, case management services, and a hospital administrator, I reluctantly agreed to sign off on the transfer.

Though the discharge plan left me feeling uncertain, I became more comfortable with the idea because our patient had the capacity to make his own decisions. He consented to return home to Mexico because it was clear that he was no longer physically able to work, and his family was also on board with the plan to help him.

A few weeks later the transfer was completed. The last I heard about the man, he had successfully arrived at the rehabilitation hospital near his hometown in Mexico.

I hadn’t thought of this case for years until the combination of a recent Shots piece about dialysis and the heated rhetoric of the election season about immigration caused the memory to bubble back up into my consciousness.

Reflecting on the man’s case, I began to wonder all over again: Who were we to send him back to Mexico? On the other hand, what alternative did we have for a safe and reasonable discharge?

I also hoped to understand if our experience was part of a broader trend or a sporadic occurrence. I could only find estimates of the number of so-called medical deportations because there isn’t any required reporting or specific oversight. It’s a murky area that falls in the gap between federal health and immigration regulations.

The best estimates suggest dozens or maybe a few hundred cases occur each year. I called several air ambulance companies to gauge the demand for such services, but none was willing to provide numbers or even go on record to discuss the practice in general.

One group that has studied the phenomenon offered a conservative estimate of 800 cases of medical deportation over a period of six years. “We field calls from across the country, so it is a national problem and not confined to border states,” Lori Nessel, director of the Center for Social Justice at Seton Hall University School of Law, told me in an email.

Even in the absence of hard numbers, the medical community has responded to the investigative reporting and advocacy around the practice. In 2012, the American Medical Association added an opinion to its Code of Medical Ethics that states, in part, a “discharge plan should be developed without regard to socioeconomic status, immigration status, or other clinically irrelevant considerations.”

A 2014 piece in The New England Journal of Medicine concluded with the opinion that doctors “…are uniquely equipped to display the moral courage necessary to advocate effectively for patients by calling attention to the profound ethical issues raised by repatriation,” using a slightly fancier word for deportation.

Health care for immigrants is a hot button issue. Though the Affordable Care Act excludes immigrants who entered the country illegally from the mandate to purchase health insurance, many U.S counties have taken steps to provide preventive and chronic care for them. The obvious rationale is that this care saves money and prevents suffering in emergency situations.

I’m confident that the transfer home of the Mexican man who’d had a stroke was both consensual and sensible. But given reports of patients being transported without their consent, this practice needs legal clarity to match the ethical aspirations of my profession.

One thing is clear: Without a policy change, hospitalized people who entered the country illegally and who don’t have insurance will remain vulnerable to the seemingly irreconcilable conflict in our society between commerce and medicine.

John Henning Schumann is a writer and doctor in Tulsa, Okla. He serves as president of the University of Oklahoma, Tulsa. He also hosts Public Radio Tulsa’s Medical Matters. He’s on Twitter: @GlassHospital.

Let’s block ads! (Why?)


No Image

Baltimore Sees Hospitals As Key To Breaking A Cycle Of Violence

Seven years ago, Johns Hopkins Hospital collaborated with Baltimore's Safe Streets program to bring violence prevention workers into the hospital to meet with the injured and settle conflicts. Now, the health department in Baltimore is trying to revive the program.

Seven years ago, Johns Hopkins Hospital collaborated with Baltimore’s Safe Streets program to bring violence prevention workers into the hospital to meet with the injured and settle conflicts. Now, the health department in Baltimore is trying to revive the program. Patrick Semansky/AP hide caption

toggle caption Patrick Semansky/AP

Every year, U.S. hospitals treat hundreds of thousands of violent injuries. Often, the injured are patched up and sent home, right back to the troubles that landed them in the hospital in the first place.

Now, as these institutions of healing are facing pressure under the Affordable Care Act to keep readmissions down, a growing number of hospitals are looking at ways to prevent violence. In Baltimore, health department workers have pitched hospitals an idea they want to take citywide.

The idea builds on the city’s Safe Streets program, which hires ex-offenders to intervene in conflicts before someone gets hurt. They’re called “violence interrupters,” and they use their street credibility and deep social ties to settle fights.

Now the health department is asking Baltimore hospitals to give the staff of Safe Streets access to patients who have been shot, stabbed or beaten up. The idea comes from Chicago, where the group CeaseFire is already working in four hospitals.

Seven years ago, Baltimore piloted such a program at Johns Hopkins Hospital. Dante Barksdale, now the outreach coordinator for Safe Streets, was one of a handful of violence interrupters trained to respond to these hospital calls.

“We had Johns Hopkins IDs,” Barksdale says. “I would walk through the hospital like I was an employee.”

When someone from the neighborhood turned up at Johns Hopkins with a violent injury, one of the hospital’s social workers would call Barksdale. He’d head over and try to talk to the patient, sometimes just as the patient was coming out of surgery, or just waking up.

The first aim, Barksdale says, is “to get him to buy into talking to me. Most of the time, people know who shot them. They know if they wronged somebody. I’m trying to get information so I can be calling out to my outreach workers.”

Barksdale’s co-workers in the neighborhood would then head out to find others who were involved, to try to prevent a retaliatory attack.

One big reason why Safe Streets is able to get people talking is because they do not work with the police. That’s earned them a certain code of honor on the street, Barksdale says.

He says that after being shot, people almost always talk.

“That right there has them vulnerable, ready to talk,” he says. “And then they see a familiar face. ‘Oh, that’s one of them Safe Street dudes. I can relate to him,’ as opposed to the chaplain, the doctor, the people who don’t know nothing about their world.”

Safe Streets outreach coordinator Dante Barksdale says right after a shooting, the injured almost always talk. “Some of them want revenge, right then and there,” he says. “Some of them are afraid. They’re thinking about their brother or their homeboy. ‘Is my man all right? He was with me!’ They’re real vulnerable. They got questions.” Patrick Semansky/AP hide caption

toggle caption Patrick Semansky/AP

“We don’t live in the neighborhood,” says Carol Stansbury, director of social work at Johns Hopkins Hospital. She says the Safe Streets workers “brought the love of their neighborhood and the love of their community that we could not bring.”

The Safe Streets program as a whole has run into trouble a few times in Baltimore; most recently in the summer of 2015, when two staffers were arrested on gun and drug charges.

Stansbury says she never had reservations about giving hospital access to the violence interrupters, almost all of whom have criminal histories.

“It makes sense to me, as a social worker, to have people that have walked the walk,” she says, “who certainly understand what the issues are, and the troubles, barriers and obstacles people face. They only help me do my job better.”

For a variety of reasons, Hopkins’ collaboration with Safe Streets was short-lived. Some of the violence interrupters who were trained as hospital responders left their jobs. The work was never funded, and the responders working in the hospital were actually needed on the streets.

But the Baltimore health department found the hospital responders program valuable, and is working to revive the concept, in a bigger way. The idea is to get six or seven hospitals on board, with hopes that at some point the hospitals will pay for it — to the tune of roughly $100,000 annually per institution. That would pay for two violence interrupters per hospital, plus someone to oversee the whole program.

The health department would also like each hospital to dedicate a social worker to the program, to help patients with follow up treatment and social services.

Several dozen hospitals around the country have violence prevention programs, but most are not staffed around-the-clock. Funding remains a challenge, with the vast majority paid for with grants or in-kind contributions.

This year, the National Network of Hospital-based Violence Intervention Programs successfully pushed to have violence prevention workers recognized as health care providers, which is a key first step to getting reimbursed by Medicaid and other insurers for services rendered.

There is a growing body of evidence that this type of public health intervention can stop the cycle of neighborhood violence that sends people repeatedly to the ER. The studies to date are small, proponents of these programs admit, but all the findings point in the same direction.

There is plenty of evidence for the need to intervene. A study out of Detroit’s Henry Ford Hospital in the 1980s is today seen as a landmark paper. Researchers tracked victims of violent crimes for five years, and found that, within that period, 44 percent suffered at least one more violent injury, and 20 percent died. A majority of these victims of violence abused alcohol or drugs, and most were unemployed.

The study concluded, “Such data suggest that efforts to reduce urban violence might fruitfully be focused on the victims of violence.”

Dr. William Jaquis, chief of emergency medicine at Baltimore’s Sinai Hospital, notes that hospitals are already spending a great deal of money on the treatment of violent injuries.

“We can look at the people who are victims of violence, and we can treat them four to six times, and obviously it’s got a tremendous cost to us,” he says. “The first time may be a blunt injury, a strike to the head. The next time may be a knife, and the next time may be a gunshot wound. I think what we find is we spend the resources anyway. And so it’s starting to look at how we spend them.”

In fact, his hospital already has informal ties to the Safe Streets operation in the nearby neighborhood of Park Heights; hospital staffers call Safe Streets when someone from the neighborhood turns up in Sinai’s ER.

Albert Brown, violence prevention coordinator for Safe Streets Park Heights, takes many of those calls. Recently, he headed to the hospital to talk with a patient who had been stabbed. After meeting with the man, he sent his colleague out to get the perpetrator’s side of the story, which he wanted to relay back to the guy in the hospital. Intervening quickly is crucial.

“He should be released any day,” Brown explains. “So the best thing to do is to hurry up and try to get on top of it, before he gets home and any retaliation or anything like that happens.”

Brown’s goal is to get the two men to sit down in a room and talk. The sooner, he says, the better.

Let’s block ads! (Why?)


No Image

Private Investors Eagerly Enter Addiction Treatment Business

The cry for more substance abuse treatment beds has not missed the ears of some private investors. They’re eager to get in on the estimated $35 billion treatment business.

Transcript

ARI SHAPIRO, HOST:

Some private equity investors are getting into the business of substance abuse treatment. They’re putting big money into building treatment centers, promising to fundamentally change the industry. It’s estimated that 22 million Americans need help with substance abuse. Deborah Becker member station WBUR reports on the huge private equity investment behind eight new facilities in the Northeast.

DEBORAH BECKER, BYLINE: The newly formed for-profit company Recovery Centers of America, or RCA, says it plans to become the nation’s largest addiction treatment provider. Its first steps toward that involve building these eight new centers, the largest of which is under construction in Danvers, a town just north of Boston.

BRAD GREENSTEIN: I’m Brad Greenstein, CEO of Recovery Centers of America Danvers facility.

BECKER: So right now we’re walking through a building that’s really been completely gutted.

GREENSTEIN: We demolished 140,000 square feet of interior, and we’re starting from scratch.

BECKER: Greenstein says this center will resemble a boutique hotel and will provide inpatient and outpatient treatment, medication-assisted treatment and will follow its patients through the initial stages of recovery. Although RCA eventually plans to build other facilities that will accept those using public insurance, this center will accept only privately insured patients or those who pay out-of-pocket, a population Greenstein says is now underserved.

GREENSTEIN: What we found not just in Massachusetts but nationwide is this lack of availability for just your average, everyday individual who’s been dutifully paying their insurance premium – are those are the ones that are generally having a hard time accessing care.

BECKER: Much of the funding for these centers comes from what some say is the largest private equity investment ever in addiction treatment – a $231 million commitment from the New York private equity firm Deerfield Management. Leslie Henshaw, a partner at Deerfield, says treatment is generating investor interest for several reasons, namely laws requiring insurers to pay for it and the Affordable Care Act allowing young people to stay on their parents’ health insurance until age 26. Henshaw says more investment will ultimately result in better care.

LESLIE HENSHAW: It’s an industry that, to date, has had very little accountability with regard to delivering on effective outcomes. And so, you know, we see both an enormous need and an imperative to change the model in which care is delivered.

BECKER: Barbara Herbert is president of the Massachusetts chapter of the American Society for Addiction Medicine.

BARBARA HERBERT: I sort of have that sense of vultures overhead who see a great opportunity to make money but not necessarily in the best interest of my patients.

BECKER: She also says that right now there are no agreed-upon minimum standards for what treatment should be. But Herbert says the metrics that investors use to measure success are often based on profits, which could mean that the more people there are in treatment, the more it’s considered a success.

HERBERT: I think the biggest metric that you need if you open a new facility is having it full and paid for. I’m not saying people are that cynical, but I’m not saying that outcomes necessarily drive investment in this circumstance.

BECKER: But some longtime Massachusetts treatment providers say if someone has the insurance or the money, they should use it, and that could free up beds for more patients. Boston University public health professor David Rosenbloom says this new growth in treatment may not only improve care with more oversight, but it could reduce the often long waits to get into treatment.

DAVID ROSENBLOOM: If this is a step toward increasing both the size and the quality and the accountability of the system, then it’s a step we have to take.

BECKER: National statistics suggest some 25 million Americans have a substance use disorder, and only about 10 percent of those who need treatment actually get it. For NPR News, I’m Deborah Becker in Boston.

Copyright © 2016 NPR. All rights reserved. Visit our website terms of use and permissions pages at www.npr.org for further information.

NPR transcripts are created on a rush deadline by a contractor for NPR, and accuracy and availability may vary. This text may not be in its final form and may be updated or revised in the future. Please be aware that the authoritative record of NPR’s programming is the audio.

Let’s block ads! (Why?)


No Image

White House Says It Will Cut Ebola Funding To Address Zika

People in Pinar del Rio, Cuba, make their way through a fumigation fog that's meant to kill the mosquito that transmits the Zika virus.

People in Pinar del Rio, Cuba, make their way through a fumigation fog that’s meant to kill the mosquito that transmits the Zika virus. Ramon Espinosa/AP hide caption

toggle caption Ramon Espinosa/AP

Top officials with the Obama administration said Wednesday that they’ll redirect $589 million toward the Zika virus response. Most of that money was to be used to deal with Ebola virus.

Almost two months ago, the Obama administration requested $1.9 billion from Congress to respond to the Zika threat.

“But Congress has yet to act,” Shaun Donovan, director of the Office of Management and Budget, said in a news conference. “In the absence of congressional action, we must scale up Zika preparedness and response activities right now.”

Over 600 people with Zika, including 64 pregnant women, have been reported in U.S. states and territories. In most cases, people contracted the virus while traveling.

But Sylvia Burwell, secretary of the U.S. Department of Health and Human Services, says she expects to see local Zika virus transmission in the continental U.S. in coming months.

The redirected funds will go to mosquito control and surveillance; education about how to prevent transmission; supporting states and territories in their own Zika virus responses; and developing vaccines and better diagnostic tests.

Burwell and Donovan reiterated that the administration’s earlier request for supplemental funding from Congress remains in place. And, they say, the administration will also ask for funds to replenish the amount currently being moved from the Ebola response to the Zika response.

Without the full supplemental funding, Burwell says, a number of crucial activities would be impacted.

“Mosquito control and surveillance might need to be delayed or stopped. Our ability to move to a subsequent phase of vaccine development could be jeopardized. And without more funding, the development of faster and more accurate diagnostics could be impaired,” says Burwell.

One reason for the haste is that public health officials want to get mosquito control and surveillance underway before the peak summer mosquito season in the U.S., and before the rainy season in Central America and the Caribbean.

Most of the redirected funding — $510 million — is coming from the Ebola response. That’s concerning, because while the public panic over Ebola has faded, the virus continues to flare up.

“We face two real global health challenges — Ebola and Zika — and we don’t have an option to set one aside in the name of the other,” says Burwell.

Last week, a woman in Liberia died of Ebola. And though Guinea was declared Ebola-free in December, last month World Health Organization officials put more than 1,000 people under medical watch because they may have come into contact with eight people who contracted Ebola.

It’s those kind of activities that could be shortchanged by diverting funds away from Ebola and toward Zika, administration officials say.

Let’s block ads! (Why?)


No Image

UVA Study Links Disparities In Pain Management To Racial Bias

NPR’s Audie Cornish speaks to Kelly Hoffman, a doctoral student in social psychology at the University of Virginia. Hoffman recently published a paper that links disparities in pain management to racial bias.

Transcript

AUDIE CORNISH, BYLINE: Numerous studies have shown that black patients are less likely than their white counterparts to receive pain medicine for the same injury. Now, new research from the University of Virginia suggests a reason why. It found that a substantial number of white medical students and residents believe black people are less sensitive to pain. Now, here to talk about the findings is UVA researcher Kelly Hoffman. Welcome to the program.

KELLY HOFFMAN: Thank you for having me.

CORNISH: First, explain how you go about even trying to measure something like this. What did this project look like?

HOFFMAN: So we measured white medical students and residents as well as white lay people’s beliefs about biological differences between blacks and whites. So we gave them a survey with items and asked them to rate the extent to which various items are true or untrue.

And we also asked them to report how much pain they thought a black patient and a white patient would feel across two scenarios. And then we asked them to tell us what pain medication they would recommend to treat each of the patient’s pain.

CORNISH: And what were some of the true and false beliefs you put in front of these participants that they had to make the call on?

HOFFMAN: So some of the true beliefs we had are things like whites are less susceptible to heart disease than blacks. Blacks are less likely to contract spinal cord diseases. And then some of the false ones and the ones that were endorsed more so were things like blacks’ blood coagulates more quickly than white people’s blood, their skin is thicker than white people’s, they have a stronger immune system than white people, and things like that.

CORNISH: What was the difference in performance between laypeople and medical students, and especially more experienced medical students, given, say, some of those false (laughter) biological beliefs that you were describing?

HOFFMAN: So what we can do is we can look at how many people essentially endorse these things as true versus untrue. And so among white laypersons, about 73 percent of the sample said that at least one of the false items was possibly, probably or definitely true whereas among the medical sample the number was around 50 percent.

CORNISH: But were you surprised, I mean, especially when it came to the medical students? I mean, don’t medical schools essentially teach students to be aware of racial biases or at least – I don’t know – some biology (laughter) that would counter some of these ideas?

HOFFMAN: Right. So what’s striking is that these beliefs seem to operate kind of independently of individual prejudice. So, I mean, it’s not the case that these particular medical students and residents are just more racially biased. It’s just these are very common beliefs that are very pervasive across our society.

CORNISH: So how does that work?

HOFFMAN: So some people think that black athletes have an extra muscle in their leg and that’s why they can jump higher and run faster, these beliefs that somehow the black body is biologically and fundamentally different, it’s stronger, it’s less impervious to pain and injury…

CORNISH: But do you see why I’m asking? I mean, some people might believe that I would hope a doctor wouldn’t.

HOFFMAN: Right. We would hope so too. And so we will need to test whether practicing physicians also hold these beliefs and whether they impact treatment in real medical context, so that’s an important question.

CORNISH: Kelly Hoffman is a researcher at UVA. Thank you so much for speaking with us.

HOFFMAN: Thank you for having me.

Copyright © 2016 NPR. All rights reserved. Visit our website terms of use and permissions pages at www.npr.org for further information.

NPR transcripts are created on a rush deadline by a contractor for NPR, and accuracy and availability may vary. This text may not be in its final form and may be updated or revised in the future. Please be aware that the authoritative record of NPR’s programming is the audio.

Let’s block ads! (Why?)


No Image

Patients Miss Out On Savings When Doctors Fail To Talk About Costs

Along with the diagnosis, patients often want to talk about how much treatment will cost.

Along with the diagnosis, patients often want to talk about how much treatment will cost. Tetra Images RF/Getty Images hide caption

toggle caption Tetra Images RF/Getty Images

Talking about money is never easy. But when doctors are reluctant to talk about medical costs, patients’ health can be undermined.

A study published Monday in the journal Health Affairs explores the opportunities that are often missed in the exam room.

Patients are increasingly responsible for more of their own health costs. In theory, financial incentives are supposed to make them sharper consumers and empower them to trim unnecessary health spending. But previous work has shown it often leads them to skimp on both valuable preventive care and superfluous testing.

Doctors could play a role in helping patients find appropriate and affordable care by talking with them about out-of-pocket costs.

But, a range of physician behaviors currently stand in the way, according to the study. “We need to prepare physicians to hold more productive conversations about health care expenses with their patients,” said Peter Ubel, a physician and behavioral scientist at Duke University.

The researchers analyzed transcripts of almost 2,000 physician-patient conversations regarding breast cancer, rheumatoid arthritis and depression treatment. They identified instances in which patients suggested the cost of care might be difficult for them to bear and assessed how doctors responded.

Overall, researchers noted two ways in which doctors dismissed patients’ financial concerns. They either didn’t acknowledge them or only addressed them halfway.

For instance, if a patient commented on how expensive a drug was, the doctor might ignore the comment entirely, or might suggest a temporary solution – like a free trial – without exploring long-term strategies to address the issue.

Without a long-term plan, patients may eventually stop taking the medication, or take it irregularly. Either way, a patient would get less benefit from treatment and could getter sicker, perhaps even winding up in the hospital.

The study doesn’t measure how often doctors dismissed patient concerns – because, the researchers wrote, they didn’t know how often those dismissals led to people actually forgoing needed treatments.

Still, Ubel said, it’s clear doctors aren’t talking to patients about these expenses. He pointed to a separate analysis of those same conversations, which found that doctors discussed medical costs with patients about 30 percent of the time. And only in a minority of those discussions did doctors and patients brainstorm about ways to make medication more affordable.

“A majority of [physicians] – they don’t talk about costs,” he said. “When they do talk about it, they don’t talk about it productively.”

Why do physicians hesitate? For one thing, they aren’t used to discussing cost barriers, and many think it’s inappropriate to bring up money at all, Ubel said. When he lectures on the subject, he always encounters people who worry that discussing finances will “contaminate the doctor-patient relationship.”

Plus, doctors haven’t been taught to listen for patients’ pocketbook concerns. If a patient comes in with heartburn and indigestion, a good internist will start probing for signs of coronary disease, Ubel said. By contrast, physicians aren’t primed to pick up on cues that patients may face financial strains.

“If we had that on our list to be aware of, we’d pick up the cues. If we don’t, it’ll be right in front of our eyes, and we’ll miss it,” he added.

The idea of patients acting as consumers – weighing cost and shopping for the best health care deal – is still relatively new, the study notes. As it becomes more commonplace, patients may push doctors for more help in making cost-based decisions, Ubel said.

That said, navigating a patient’s financial circumstances and medical needs in the course of a 15-minute visit is tricky, said Jonathan Kolstad, an assistant professor of economic analysis and policy at the University of California, Berkeley. Kolstad wasn’t involved in the Health Affairs study but has researched how medical costs affect people’s decision-making.

“It’s not as though, ‘Oh, it’s just consumers can’t figure it out.’ Doctors don’t know,” he said. When it comes to figuring out what a drug will cost, doctors are in the same boat.”

Kaiser Health News is an editorially independent news service that is part of the nonpartisan Henry J. Kaiser Family Foundation. Shefali Luthra is on Twitter: @shefalil.

Let’s block ads! (Why?)


No Image

Malware Attacks On Hospitals Put Patients At Risk

Hackers crippled computer systems at several MedStar hospitals, including the Georgetown University Hospital in Washington, D.C.

Hackers crippled computer systems at several MedStar hospitals, including the Georgetown University Hospital in Washington, D.C. Molly Riley/AP hide caption

toggle caption Molly Riley/AP

The first sign seems innocuous enough if you don’t know what you’re looking at: Files in the computer appear as decrypt.html, or decrypt.txt instead of their usual names.

Then, you click. A box pops up that gives you an ultimatum: Want the file? You’ll have to pay up, and probably in bitcoin.

That is what happened at U.S. hospitals in the past month in California, Kentucky, Maryland and the District of Columbia. The malware attacks have left the 14 hospitals — 10 of which are part of the MedStar hospital group — unable to access patient data and, in some cases, having to turn patients away.

Hospitals are not alone in their vulnerability; last month, a cafe in Maryland was hit with a ransomware attack. In another instance, Mac computers were targeted. Last year, police in Massachusetts paid hackers to return access to their data. Companies and individuals in the U.S. lost more than $24 million to ransomware in 2015, according to the FBI.

And in February at the Hollywood Presbyterian Medical Center in Los Angeles, administrators paid the asking price of 40 bitcoin, about $16,664 at the time, to regain access to their data. At MedStar, the hospital is being asked to pay 45 bitcoin.

Several MedStar employees saw a message on their computer screens: “You just have 10 days to send us the Bitcoin. After 10 days we will remove your private key and it’s impossible to recover your files.”

“The big difference with health care is that the consequences are greater,” Kevin Fu, an associate professor at the University of Michigan who studies computer security issues in hospitals, told the MIT Technology Review. “You can lose your email and that’s annoying, but patient records are needed in order to treat patients.”

Though bitcoin is not in itself a driver of cybercrime, it allows the hackers to have instant access to the money without its having to go through a bank or credit card. Peter Van Valkenburgh, director of research at Coin Center, a nonprofit dedicated to digital currency advocacy, explains that often the ransomware will include easy-to-follow instructions on how to quickly access and trade bitcoin.

Hospitals hit by the attack felt the pressure of being without patient information. At a MedStar hospital, a patient was given an antibiotic that, a nurse told the Washington Post, “should have been stopped eight hours earlier.” At the Hollywood Presbyterian Medical Center last month, patients were diverted to other hospitals. In both situations, the hospitals returned to paper records.

On its website Thursday, MedStar posted: “MedStar Health’s priority continues to be providing high quality, safe patient care, as we work to fully restore all of our major IT systems. Our doors remain open, with a few exceptions. With the dedication and commitment of our clinicians and associates, we are thankful that we have been able to perform more than 1,000 surgeries since Monday morning’s malicious malware attack.”

Rick Pollack, president and CEO of the American Hospital Association, emphasizes that hospitals should take steps to protect patient data: “Hospital leaders are using the lessons learned in previous attacks and are applying best cybersecurity practices shared by the AHA in an effort to anticipate and respond to existing and emerging threats,” he says.

The FBI is investigating several of these recent attacks. An FBI official tells NPR:

“Companies can prevent and mitigate malware infection by utilizing appropriate backup and malware detection and prevention systems, and training employees to be skeptical of emails, attachments, and websites they don’t recognize. The FBI does not condone payment of ransom, as payment of extortion monies may encourage continued criminal activity, lead to other victimizations, or be used to facilitate serious crimes.”

Hospitals can take a variety of steps to safeguard against these kinds of attacks, like using HTTPS encryption, two-factor authentication and implementing file backups on a separate server. “For hospitals right now, backups of customer data on unconnected machines or machines in other networks is essential,” Van Valkenburgh says.

He adds that patients should have more control over who has access to their personal records, and when. But until then? “We really are at the mercy of these centralized institutions,” he says.

Naomi LaChance is a business news intern at NPR.

Let’s block ads! (Why?)


No Image

FDA Approves Experimental Zika Screening For Blood Donations

On Wednesday, the FDA approved an experimental test that screens blood donations for the Zika virus. It’s a response to a blood donation shortage in Puerto Rico, where local donations were halted out of fear of spreading the virus.

Transcript

KELLY MCEVERS, HOST:

The federal government has been paying for blood banks around the country to ship blood to Puerto Rico. The FDA issued guidelines last month to stop blood donations on the island because of the Zika virus. The virus is most commonly transmitted through mosquitoes, but Brazil has reported cases of transmission through blood transfusions. Puerto Rico has more than 300 reported Zika cases.

Within the next week or two, Puerto Rico will be able to start collecting blood again. That’s because the FDA has just give the go-ahead to a new test to screen blood donations for the virus. Peter Marks is the director of the FDA’s Center for Biologics Evaluation and Research. Welcome to the show.

PETER MARKS: Thanks very much.

MCEVERS: This test was developed by the drug company Roche, and it will be used on what’s called an investigational basis. First, can you tell us what that means?

MARKS: So investigational use of a test means that data continue to be collected on the tests performance at specific participating sites that are conducting the test. And that means that the test itself has not yet received approval to be marketed commercially.

MCEVERS: Is there any question at all about whether or not this test actually works?

MARKS: So the best way that I can answer that is to say that, yes, the test is under investigational use. But before we allowed this investigation – new drug application to proceed, we carefully considered any potential risks prior to determining that it was safe for it to proceed.

And we also considered the possibility that the test might malfunction in a manner that could put patients at risk. And we consider the latter really highly unlikely. So we feel that it was reasonable to allow this test to proceed at this time.

MCEVERS: OK. I mention that blood banks from all over the U.S. have been sending blood to Puerto Rico. Was there a real possibility of a blood shortage if Zika were to spread to Florida or other Gulf states?

MARKS: The good news is that currently, the blood supply in the United States is quite adequate. And there actually is an interorganizational disaster task force which has been monitoring the situation and feels that, at least at this point, the blood supply would be adequate to meet the needs would there have been spread of Zika to a larger area on the continental United States.

MCEVERS: So let’s say if Zika were to be transmitted elsewhere in the U.S., could this test be rolled out quickly to affected areas?

MARKS: So I’m going to have to defer part of that to the sponsor, Roche. But my understanding is that they are aware of the potential need that this could be a larger outbreak than the existing one in Puerto Rico.

MCEVERS: If you can, put this in perspective for us in terms of other developments regarding Zika.

MARKS: So in terms of the perspective of having a blood screening test, I would say that this is a major step forward in helping to keep the blood supply safe. It will allow blood to potentially be collected in areas where there is active transmission, which is quite important for something like Zika which could be transmitted by either mosquitoes or could possibly be sexually transmitted. So we feel it is a step forward.

MCEVERS: Dr. Peter Marks heads the FDA’s Center for Biologics Evaluation and Research. Thank you very much.

MARKS: Thank you.

Copyright © 2016 NPR. All rights reserved. Visit our website terms of use and permissions pages at www.npr.org for further information.

NPR transcripts are created on a rush deadline by a contractor for NPR, and accuracy and availability may vary. This text may not be in its final form and may be updated or revised in the future. Please be aware that the authoritative record of NPR’s programming is the audio.

Let’s block ads! (Why?)


No Image

Obama Task Force Director On The Cancer 'Moonshot' Initiative

NPR’s Audie Cornish talks with Greg Simon, executive director of the Obama administration’s Cancer Moonshot Task Force, about the barriers to advancements in treating cancer.

Transcript

AUDIE CORNISH, HOST:

Back in January at the president’s State of the Union address, there was one ambitious announcement that stood out.

(SOUNDBITE OF ARCHIVED RECORDING)

BARACK OBAMA: Let’s make America the country that cures cancer once and for all. What do you think, Joe?

(CHEERING)

CORNISH: President Obama put Vice President Joe Biden in charge of what is now called the Cancer Moonshot Task Force. The mission is as ambitious as putting a man on the moon used to be – eliminate cancer as we know it. The task force now has an executive director – Greg Simon. He’s been on the job for a week and a half, and he joins me now. Greg Simon, welcome to the program.

GREG SIMON: Thank you.

CORNISH: So talk about exactly what this task force is supposed to do, especially in so short a period of time, right? President Obama’s tenure’s coming to a close.

SIMON: Well, it is a short period of time, but there are very few problems that are holding us back in cancer research that are unknown. We know what the problems are, and now we need to start the action to deal with those problems because the overarching goal of this initiative is to achieve 10 years of progress in five years.

Now, there are some things that can’t be speeded up. You can’t do a three-minute egg in one minute, but you don’t have to spend six weeks setting it up. And that’s often what we do in science. So we’re looking at, how can we share data from cancer centers to cancer centers to accelerate knowledge transfer? We’re looking at how to communicate with the public the importance of being in clinical trials. We’re looking at the importance of the pharmaceutical industry of opening up their compound libraries for more people to explore possible therapeutic agents in those libraries.

CORNISH: You mentioned this idea of getting different cancer center databases to share information. What are the obstacles to that right now?

SIMON: Well, there are cultural obstacles. People tend to want to keep the data in their institution because that data is valuable. It can lead to new therapies. It can lead to new ways to treat patients, and people want them to come to their center.

Our technology for sharing has improved faster than our attitude about sharing, and that’s part of what the vice president is doing – is helping change that attitude so that people realize the more you share, the more you have.

CORNISH: Now, you have worked with the medical company Pfizer. You’ve worked with nonprofits in the cancer care industry. Fundamentally, this is still business, and people are competing with each other.

SIMON: That’s true, but this is sort of the tragedy of the commons example. If people don’t take care of a common space, it deteriorates, and everybody suffers. The common space here is people surviving cancer. Academia is not very good at taking a drug to market, and they’re not very good, and they shouldn’t be that good at raising billions of dollars for those clinical trials and the cost of bringing a drug to market.

The pharmaceutical industry is very good at clinical trials and marketing, but they tend not to often have the trust of the people they’re trying to help. There are many foundations that want to partner with the pharmaceutical industry to do research into a rare disease that would otherwise not be funded. And the foundations bring money, and they bring patients. But what they don’t have are the scientists to develop the drug.

And those collaborations are a way that we can link patient community and the pharmaceutical community for both people’s benefits.

CORNISH: Do you worry about overselling what can accomplished here? I mean, it’s called the Cancer Moonshot Initiative. Do you think people think you’re going to cure caner altogether?

SIMON: Well, we try to avoid giving the impression that in between now and the end of term we’re going to cure cancer now and forever, but what we can do, is we can identify what needs to be done and put the power of the vice president and the president behind it while we’re here and create a blueprint for any next administration to take this forward because the kind of issues we’re dealing with are things that can ease the path for the scientist out there to do their job better.

You know, I always say that the people who are in the system don’t have the time to fix the system. They’re too busy trying to save our lives with new drugs and therapies. But those of us on the outside – it’s our job to fix the system. And there are plenty of things in the system that are totally amenable to being improved this year and over the next several years that will save lives.

CORNISH: Greg Simon is executive director of the White House Cancer Moonshot Task Force. Thank you so much for speaking with us.

SIMON: Thank you.

Copyright © 2016 NPR. All rights reserved. Visit our website terms of use and permissions pages at www.npr.org for further information.

NPR transcripts are created on a rush deadline by a contractor for NPR, and accuracy and availability may vary. This text may not be in its final form and may be updated or revised in the future. Please be aware that the authoritative record of NPR’s programming is the audio.

Let’s block ads! (Why?)